HRP20120019T1 - Nova uporaba kinolonskih antibiotika - Google Patents
Nova uporaba kinolonskih antibiotika Download PDFInfo
- Publication number
- HRP20120019T1 HRP20120019T1 HR20120019T HRP20120019T HRP20120019T1 HR P20120019 T1 HRP20120019 T1 HR P20120019T1 HR 20120019 T HR20120019 T HR 20120019T HR P20120019 T HRP20120019 T HR P20120019T HR P20120019 T1 HRP20120019 T1 HR P20120019T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- represents hydrogen
- spp
- cyanoquinolone
- carbon atoms
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title claims abstract 4
- 229940088710 antibiotic agent Drugs 0.000 title claims abstract 4
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title 1
- VTAJXTQJNZWWGT-UHFFFAOYSA-N 2-oxo-1h-quinoline-8-carbonitrile Chemical compound C1=CC(C#N)=C2NC(=O)C=CC2=C1 VTAJXTQJNZWWGT-UHFFFAOYSA-N 0.000 claims abstract 4
- 210000000214 mouth Anatomy 0.000 claims abstract 3
- 208000035143 Bacterial infection Diseases 0.000 claims abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 230000009885 systemic effect Effects 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- -1 alkyl radical Chemical class 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241001148536 Bacteroides sp. Species 0.000 claims 1
- 241000589996 Campylobacter rectus Species 0.000 claims 1
- 241000190885 Capnocytophaga ochracea Species 0.000 claims 1
- 241000588878 Eikenella corrodens Species 0.000 claims 1
- 241000605909 Fusobacterium Species 0.000 claims 1
- 241000191992 Peptostreptococcus Species 0.000 claims 1
- 241000605894 Porphyromonas Species 0.000 claims 1
- 241000605861 Prevotella Species 0.000 claims 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229960001248 pradofloxacin Drugs 0.000 claims 1
- LZLXHGFNOWILIY-APPDUMDISA-N pradofloxacin Chemical compound C12=C(C#N)C(N3C[C@H]4NCCC[C@H]4C3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 LZLXHGFNOWILIY-APPDUMDISA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10337191A DE10337191A1 (de) | 2003-08-13 | 2003-08-13 | Neue Verwendung von Chinolon-Antibiotika |
| PCT/EP2004/008629 WO2005018641A2 (de) | 2003-08-13 | 2004-08-02 | Chinolon-antibiotika zur behandlung von periodontalen infektionen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120019T1 true HRP20120019T1 (hr) | 2012-02-29 |
Family
ID=34201505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120019T HRP20120019T1 (hr) | 2003-08-13 | 2012-01-09 | Nova uporaba kinolonskih antibiotika |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US8658645B2 (ko) |
| EP (1) | EP1656143B1 (ko) |
| JP (2) | JP5122814B2 (ko) |
| KR (1) | KR101209119B1 (ko) |
| CN (1) | CN100571702C (ko) |
| AR (2) | AR045093A1 (ko) |
| AT (1) | ATE528004T1 (ko) |
| AU (2) | AU2004266452A1 (ko) |
| BR (1) | BRPI0413509A (ko) |
| CA (1) | CA2535637C (ko) |
| CY (1) | CY1112167T1 (ko) |
| DE (1) | DE10337191A1 (ko) |
| DK (1) | DK1656143T3 (ko) |
| ES (1) | ES2374728T3 (ko) |
| GT (1) | GT200400156A (ko) |
| HK (1) | HK1098687A1 (ko) |
| HR (1) | HRP20120019T1 (ko) |
| IL (1) | IL173655A (ko) |
| LU (1) | LU91883I2 (ko) |
| MX (1) | MXPA06001597A (ko) |
| MY (1) | MY162652A (ko) |
| NO (1) | NO333116B1 (ko) |
| NZ (1) | NZ545261A (ko) |
| PE (1) | PE20050341A1 (ko) |
| PL (1) | PL1656143T3 (ko) |
| PT (1) | PT1656143E (ko) |
| RU (1) | RU2367437C2 (ko) |
| SI (1) | SI1656143T1 (ko) |
| TW (1) | TWI367095B (ko) |
| UA (1) | UA85685C2 (ko) |
| UY (1) | UY28465A1 (ko) |
| WO (1) | WO2005018641A2 (ko) |
| ZA (1) | ZA200601167B (ko) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10337191A1 (de) * | 2003-08-13 | 2005-03-17 | Bayer Healthcare Ag | Neue Verwendung von Chinolon-Antibiotika |
| TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| FR2896416B1 (fr) * | 2006-01-24 | 2010-08-13 | Vetoquinol | Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine |
| DE102006010643A1 (de) * | 2006-03-08 | 2007-09-13 | Bayer Healthcare Aktiengesellschaft | Arzneimittel enthaltend Fluorchinolone |
| DE102006049520A1 (de) | 2006-10-20 | 2008-04-24 | Bayer Healthcare Ag | Verfahren zur Herstellung von Pradofloxacin |
| DE102007055341A1 (de) * | 2007-11-19 | 2009-05-20 | Bayer Animal Health Gmbh | Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren |
| WO2010069493A1 (de) * | 2008-12-18 | 2010-06-24 | Bayer Animal Health Gmbh | Verbesserte wirkstoffkombination enthaltend ein antibiotikum und einen nichtsteroidalen entzündungshemmer (nsaid) |
| CN102988280B (zh) * | 2012-10-08 | 2014-03-19 | 新乡医学院 | 一种加雷沙星滴眼剂 |
| JP6358868B2 (ja) * | 2014-06-17 | 2018-07-18 | Ｄｓファーマアニマルヘルス株式会社 | オルビフロキサシンを含有する製剤組成物 |
| CN106831795B (zh) * | 2017-01-16 | 2018-12-21 | 石家庄学院 | 喹诺酮异土木香内酯衍生物及其制备和应用 |
| CA3098060A1 (en) | 2018-04-25 | 2019-10-31 | Bayer Animal Health Gmbh | Process for the hydrolysis of quinolone carboxylic esters |
| US20230148194A1 (en) | 2019-11-28 | 2023-05-11 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62205060A (ja) * | 1986-03-04 | 1987-09-09 | Kyorin Pharmaceut Co Ltd | ８位置換キノロンカルボン酸誘導体 |
| DE3702393A1 (de) * | 1987-01-28 | 1988-08-11 | Bayer Ag | 8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo- 3-chinolincarbonsaeuren, verfahren zu ihrer herstellung und diese enthaltende antibakterielle mittel |
| JP4338217B2 (ja) * | 1996-02-23 | 2009-10-07 | バイエル・アニマル・ヘルス・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 置換可能な８―シアノ―１―シクロプロピル―７―（２，８―ジアザビシクロ―［４．３．０］―ノナン―８―イル）―６―フルオロ―１，４―ジヒドロ―４―オキソ―３―キノリンカルボン酸およびそれらの誘導体 |
| TW415943B (en) * | 1996-06-28 | 2000-12-21 | Bayer Ag | 7-(3-vinyl-1,4-piperazin-1-yl)-substituted quinolonecarboxylic acids |
| DE19633480A1 (de) * | 1996-08-20 | 1998-02-26 | Bayer Ag | Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren |
| DE19652219A1 (de) * | 1996-12-16 | 1998-06-18 | Bayer Ag | Verwendung von 7-(1-Aminomethyl-2-oxa-7-azabicyclo[3.3.0]oct-7-yl)-chinolon- und naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen |
| WO1999010351A1 (fr) * | 1997-08-22 | 1999-03-04 | Dainippon Pharmaceutical Co., Ltd. | Derives d'acide pyridonecarboxylique et intermediaires aux fins de leur preparation |
| DE19962470A1 (de) | 1999-12-22 | 2001-07-12 | Schulz Hans Herrmann | Verwendung von Chemotherapeutika |
| DE10337191A1 (de) * | 2003-08-13 | 2005-03-17 | Bayer Healthcare Ag | Neue Verwendung von Chinolon-Antibiotika |
-
2003
- 2003-08-13 DE DE10337191A patent/DE10337191A1/de not_active Withdrawn
-
2004
- 2004-07-23 AR ARP040102624A patent/AR045093A1/es not_active Application Discontinuation
- 2004-08-02 PL PL04763700T patent/PL1656143T3/pl unknown
- 2004-08-02 CN CNB2004800299003A patent/CN100571702C/zh not_active Expired - Lifetime
- 2004-08-02 CA CA2535637A patent/CA2535637C/en not_active Expired - Lifetime
- 2004-08-02 JP JP2006522943A patent/JP5122814B2/ja not_active Expired - Lifetime
- 2004-08-02 RU RU2006107497/15A patent/RU2367437C2/ru active
- 2004-08-02 UA UAA200602704A patent/UA85685C2/ru unknown
- 2004-08-02 ES ES04763700T patent/ES2374728T3/es not_active Expired - Lifetime
- 2004-08-02 BR BRPI0413509-1A patent/BRPI0413509A/pt not_active Application Discontinuation
- 2004-08-02 PT PT04763700T patent/PT1656143E/pt unknown
- 2004-08-02 WO PCT/EP2004/008629 patent/WO2005018641A2/de active Application Filing
- 2004-08-02 SI SI200431807T patent/SI1656143T1/sl unknown
- 2004-08-02 DK DK04763700.4T patent/DK1656143T3/da active
- 2004-08-02 NZ NZ545261A patent/NZ545261A/en not_active IP Right Cessation
- 2004-08-02 MX MXPA06001597A patent/MXPA06001597A/es active IP Right Grant
- 2004-08-02 AT AT04763700T patent/ATE528004T1/de active
- 2004-08-02 US US10/567,057 patent/US8658645B2/en active Active
- 2004-08-02 AU AU2004266452A patent/AU2004266452A1/en not_active Abandoned
- 2004-08-02 EP EP04763700A patent/EP1656143B1/de not_active Expired - Lifetime
- 2004-08-02 KR KR1020067002816A patent/KR101209119B1/ko active IP Right Grant
- 2004-08-11 UY UY28465A patent/UY28465A1/es not_active Application Discontinuation
- 2004-08-11 GT GT200400156A patent/GT200400156A/es unknown
- 2004-08-11 MY MYPI20043261A patent/MY162652A/en unknown
- 2004-08-11 PE PE2004000780A patent/PE20050341A1/es not_active Application Discontinuation
- 2004-08-12 TW TW093124130A patent/TWI367095B/zh not_active IP Right Cessation
-
2006
- 2006-02-09 ZA ZA200601167A patent/ZA200601167B/en unknown
- 2006-02-09 IL IL173655A patent/IL173655A/en active IP Right Grant
- 2006-03-08 NO NO20061127A patent/NO333116B1/no unknown
-
2007
- 2007-05-15 HK HK07105144.7A patent/HK1098687A1/xx not_active IP Right Cessation
-
2011
- 2011-01-28 AU AU2011200356A patent/AU2011200356B2/en not_active Expired
- 2011-10-12 LU LU91883C patent/LU91883I2/fr unknown
- 2011-12-16 CY CY20111101253T patent/CY1112167T1/el unknown
-
2012
- 2012-01-09 HR HR20120019T patent/HRP20120019T1/hr unknown
- 2012-06-27 JP JP2012144576A patent/JP2012211170A/ja active Pending
-
2017
- 2017-09-13 AR ARP170102528A patent/AR109644A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120019T1 (hr) | Nova uporaba kinolonskih antibiotika | |
| ATE261444T1 (de) | Pyrazolopyridine | |
| CY1114210T1 (el) | Απο του στοματος μορφη δοσολογιας περιλαμβανουσα αναστολεα pde 4 ως δραστικο συστατικο και πολυβινυλοπυρρολιδονη ως εκδοχο | |
| IS7214A (is) | Samsetningar sem samanstanda af sefalósporin efnasambandi og notkun þeirra við meðhöndlun á bakteríusýkingum í köttum og hundum | |
| PT1268480E (pt) | Derivados de 8-quinolinil-xantina e 8-isoquinolinil-xantina como inibidores da pde 5 | |
| EE200300359A (et) | Asendatud asaindooloksoatseetpiperasiini derivaatide koostis ja viirusevastane toime | |
| DE60334016D1 (de) | Antibakterielle mittel | |
| IS7952A (is) | Salt af naftýridín karboxýlsýru afleiðu | |
| CA2238410A1 (en) | Novel indole-2,3-dione-3-oxime derivatives | |
| HUP0203716A3 (en) | Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect and pharmaceutical compositions containing them | |
| EE200200075A (et) | Peroraalselt ja paikselt manustatavad farmatseutilised kompositsioonid | |
| DE60022227D1 (de) | 2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung | |
| EE9800259A (et) | Kamptotetsiinderivaadid ja nende kasutamine kasvajavastaste ainetena | |
| AU7882600A (en) | Lesion-directed dry dosage forms of antibacterial agents for the treatment of acute mucosal infections of the oral cavity | |
| ATE179421T1 (de) | Benzopyranderivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| CY1105373T1 (el) | Ισοκινολινυλικα καρβοξαμιδια και η χρηση τους ως αντισπαστικα | |
| GB9908192D0 (en) | Bis(acridinecarboxamide) and bis(phenazinecarboxamide) as antitumour agents | |
| HRP20201793T1 (hr) | 1,2,4-triazolo-[3,4-b]-1,3,4-tiadiazol derivati | |
| BG106922A (en) | Heterocyclic amide derivatives | |
| NO963374D0 (no) | Substituerte 4H-pyraner | |
| AR003420A1 (es) | Composiciones antibacterianas a base de n-oxidos de heterociclos saturados que contienen nitrogeno, y uso de los mismos para la produccion de composiciones | |
| DE60326710D1 (de) | Trizyklische antibakterielle makrolidderivate | |
| ECSP993176A (es) | Nuevos compuestos y composiciones antibacterianas | |
| MA26693A1 (fr) | Compositions pour administration par voie buccale | |
| PT100348A (pt) | Derivados de imidazoquinoxalinas que constituem uma nova classe de ligandos do receptor cerebral do acido alfa-aminobutirico {gaba} |